SIAC was set up to identify and build on evolving science trends in the biotech industry that can give the UK competitive advantage.
The aims of the committee are to:
- Influence the policy of government and funders of UK science and technology through proactive engagement with key stakeholders to the benefit of UK life science companies
- Encourage active networking between BIA member companies to facilitate communication, collaboration and sharing of best practice for mutual benefit
- Improve translational science through more effective interaction between the academic research community, TTOs and BIA members
- Address the identified science skills shortage in UK life sciences
- Further engagement with CSO community along with continued engagement with CMO community
- Support the delivery of the inaugural BIA CMO Forum in March 2018
- Support the delivery of a lunch in May 2018 bringing stakeholders together to discuss industry engagement with UKRI
- Deliver draft paper ‘Manufacturing Science for the Health Life Sciences’ to argue importance of early stage research funding to bioprocessing
- Influence relevant areas of science policy as Life Science Industrial Strategy and Sector Deals emerge, e.g. long-term funding environment and clinical trials
- Engage with UKRI
Committee Chair: Dr Mark Carver
Committee vice-Chair: Dr Penny Ward, PWG Consulting
For more information contact Annette England, Bioprocessing Consultant
SIAC brought together representatives from across the biotech/healthcare community to discuss technology transfer. This followed the recent Dowling Report, and also the evidence given and the subsequent report by the House of Commons Science and Select Committee on managing academic intellectual property. The BIA’s intention is to address some of the issues highlighted, such as friction around IP licencing, by bringing together all the relevant parties, and encouraging open dialogue.
The Patient is waiting workshop
SIAC and Faculty of Pharmaceutical Medicine (FPM) brought together representatives from Biotech, Pharma, the MHRA, Academia and Medical Charities in April 2017 to discuss strategic options for expediting clinical research. The combined experience of the workshop attendees from across the biotech/healthcare community reinforces the fact that the United Kingdom remains an extremely attractive region in which to conduct the clinical development of new treatments modalities; both early and late phase - read the workshop summary for further details.
Chief Medical Officer Summit
The BIA Chief Medical Officer Summit was a new event held in early March 2018 aimed at supporting the skills required to be a CMO in an SME. Here, Dr Penny Ward, vice-Chair of the BIA SIAC, takes a look at some of the highlights from the day.
One of SIAC's roles is to input into relevant consulations including NHS England's consultation on clinical research
Advanced Centre for Biochemical Engineering, University College London
The Advanced Centre for Biochemical Engineeering hosts the MBI® Modular Training Programme for the Bioindustries.
Aptus Clinical Limited
Aptus Clinical is a specialist UK- based oncology CRO, committed to partnering with clients to transform their promising molecules into valued medicines.
Astex Pharmaceuticals Ltd
Astex Pharmaceuticals is using an innovative, fragment-based drug discovery platform, Pyramid™, to identify and develop new medicines, primarily for the treatment of cancer.
Autolus is biotechnology company focussed on the development and commercialisation of engineered T-cell therapies for haematological and solid tumours.
Cell and Gene Therapy Catapult
The Cell and Gene Therapy Catapult was established in 2012 as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation.
CellCentric is a drug discovery company focused on epigenetics, a major new area for novel small molecule therapeutics. The company is pursuing novel treatments for prostate, breast and amongst other cancers.
Censo Biotechnologies Ltd
Censo is a leading producer/user of induced Pluripotent Stem Cells (iPSCs) and their derivatives for drug discovery.
Cobra provides a comprehensive biopharmaceuticals service offering, with multi-functional project teams nurturing products from pre-clinical to commercial scale GMP manufacture.
GSK is a global pharmaceutical company dedicated to helping people feel better, do more and live longer.
Heptares Therapeutics Ltd
Heptares is a pioneer in the discovery of new medicines targeting G-protein-coupled receptors (GPCRs), a super-family of proteins linked to many human diseases.
Innovate UK is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government.
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2010
Karus Therapeutics Ltd
Karus is an emerging pharmaceutical company whose R&D activities are focused on the design and development of innovative, molecular-targeted, small molecule drugs to treat immune/inflammatory disorders and cancer.
LGC is an international science-based company and market leader in analytical, forensic, biotechnology, diagnostic and product services and reference standards.
LifeArc is the new name for MRC Technology, a medical research charity with a 25 year legacy of helping scientists and organisations turn their research into treatments and diagnostics for patients.
London School of Hygiene and Tropical Medicine
The London School of Hygiene & Tropical Medicine is a leading postgraduate institution worldwide for research and postgraduate education in public and global health. Part of the University of London, the London School is the largest institution of its kind in Europe with a remarkable depth and breadth of expertise encompassing many disciplines. It is one of the highest-rated research institutions in the UK.
Medicines Discovery Catapult
The Medicines Discovery Catapult (MDC) is the centre of national, independent expertise for the discovery and proof of new medicines.
The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) is an independent scientific organisation. Tasked by Government, the NC3Rs supports the UK science base by driving and funding innovation and technological developments that replace or reduce the need for animals in research and testing, and lead to improvements in welfare where animals continue to be used. The Centre promotes robust and ethical scientific practice through collaborating with research funders, academia, industry, regulators and animal welfare organisations, both in the UK and internationally. The NC3Rs is supported primarily by Government, but also receives funding from the charitable and industrial sectors. It has an annual budget of approximately £6.1 million and is the UK’s major funder of 3Rs research. Further information about NC3Rs activities and programmes can be found at www.nc3rs.org.uk
Oxford BioMedica plc
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs.
Pall Life Sciences
Pall Corporation (NYSE:PLL) is a global leader in the high-tech filtration, separation and purification industry. We’ve become an industry leader by helping a diverse range of customers solve complex fluid management challenges.
A forward-thinking commercial and private client law firm delivering imaginative and incisive advice – both in the UK and internationally. From cross-border technology transfer agreements to sophisticated tax affairs, our solicitors have the expertise to achieve results.
Pinsent Masons is a full-services law firm with offices across the UK, Europe and Asia offering the very highest level of market intelligence and experience.
PWG Consulting (Biopharma) Ltd
Clinical development consulting and medical adviser services for investors, start-ups and SMEs in the biotechnology and medical device sectors.
Global leaders in synthetic promoter construction for customised gene regulation and protein expression in all biotechnology applications.
To be the first choice provider of innovation support for technology R&D organisations throughout the UK; accessing funding, R&D tax credits and evaluating market and technology opportunities through a professional, honest and vibrant service which delivers consistent success" TBAT Innovation specialises in assisting its clients to access funds through numerous sources. This includes: - Grant funding through UK and EU programmes - R&D tax credits through HMRC - A range of additional sources of funding to enable growth through private investors, venture capital and business loans TBAT Innovation is currently a team of 16 employees and continually growing. Within the team there is experience across numerous technologies and industry sectors including health, genetics, sensors, photonics, electronics, advanced materials, aerospace and transport amongst others. Over the last 12 months the team has assisted clients in accessing over £20m in grant funding through UK and EU grant sources. Success rates over grant funding competitions has constantly been over 75% over the last 3 years. In addition, TBAT has assisted clients in accessing over £8m in R&D Tax Credits benefits through HMRC and our success rate for claims is 100%. In parallel to this, the team has over 10 years’ experience of positioning, reviewing and structuring private investment deals.
Trio Medicines is a pharmaceutical company, a subsidiary of Hammersmith Medicines Research (HMR), a clinical research organisation founded in 1993.
A global biopharma focused on severe diseases with operations in more than 40 countries and global revenue of € 3.2 billion in 2010.
University of Nottingham
The University of Nottingham is a pioneering university. A place where world-leading research transforms lives and shapes the future.
University of Southampton
The University of Southampton is one of the world's leading entrepreneurial and research universities, with an impressive track record as a partner to business and as a source of invention and innovation. We are a dynamic, international community dedicated to scholarship, discovery and enterprise. We have a focused and managed research strategy and are intent on maximising clinical translation from the highest quality basic biomedical research. The University has a unique commitment to innovation, which is evidenced both in our outstanding research, entrepreneurial culture and also in our ability to pioneer new approaches and techniques relevant to the world today. As a University we support the world-class research of our academics by focusing on its impact on national and global economies and society. We develop and maintain relationships with external partners and help exploit our research outputs for the benefit of society. The University has a 40-year history of collaborating with industry. Our list of business partners includes Airbus, QinetiQ, IBM,Rolls Royce, BAE Systems, Luxfer, DePuy, Abbott, GSK, Lloyds Register, RNLI, Philips, Vitacress, Microsoft and Eli Lilly. Around 40 per cent of UK funded research at Southampton is financed by industry and public sector organisations. Our researchers work with all types of business to assist in developing new products and innovative processes and our partners can gain access to government and EU research funding.
Valirx wants to make a structural change in science, namely to engineer a scientific breakthrough into human health and wellbeing, through early detection of disease and therapeutic intervention.
Wellcome Trust Sanger Institute
The mission of the Wellcome Trust Sanger Institute is to use genome sequences to improve human health by advancing understanding of the biology of humans and pathogens.